Clinical Trial Update: Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing immunogenicity and reactogenicity of PCV13 in infants and children in Burkina Faso; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Agence de Médecine Préventive, France | Conditions: Pneumococcal Infections | Phase 4 | Status: COMPLETED